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Purpose: Inappropriate contact lens (CL) use and care often lead to corneal neovascularization (corneal NV). We used
mouse eyes which wore CL as the animal model to assess the reason for corneal NV with CL wear. The similar and
overlapping activity of vascular endothelial growth factor (VEGF) and the potent angiogenic hypoxia-inducible factor
1α (HIF-1α) called for a study of the temporal relationship in the expression of these two autocoids. We determined the
time dependent expression of HIF-1α and correlated it to that of VEGF expression in the mouse model of closed eye with
CL wear.
Methods: Mouse eyes were fitted with CL followed by a silk suture tarsorrhaphy. The anterior surface was analyzed at
4, 7, and 10 days after tarsorrhaphy by slit lamp and corneal NV. HIF-1α and VEGF levels were measured by reverse
transcription PCR, western blotting and immunofluorescence with specific primers and antibodies. We used shRNA
targeting HIF-1α to substantiate the link between HIF-1α, VEGF expression, and angiogenesis in the CL wear model.
Results: Corneal NV scores increased in a time dependent manner in the model of closed eye CL induced hypoxic injury.
Corneal epithelial HIF-1α and VEGF expression increased in a time dependent manner. The prolonged hypoxic state
brought by closed eye CL wear induced a time dependent neovascular response which was significantly attenuated by
HIF-1α specific shRNA but not by nonspecific shRNA. Both HIF-1α and VEGF levels were reduced significantly in
corneal homogenates from eyes treated with the HIF-1α specific shRNA.
Conclusions: The present study documented the increased expression of HIF-1α in the corneal epithelium during CL
wear. It also demonstrated the presence of VEGF in the corneal epithelium and its increased expression in this model.
Altogether, the results of this study raised the possibility of interaction between HIF-1α and VEGF, in mediating the
neovascularization response induced by the prolonged hypoxic state brought about by closed eye CL wear. The results
strongly implicated corneal HIF-1α as a component of the inflammatory and neovascular cascade initiated by hypoxic
and further suggested that HIF-1α was a proximal regulator of VEGF expression in this model.
Since contact lens (CL) was introduced in the USA in the
1950s,  advances  in  CL  technology  have  enabled  great
improvements to be made in CL safety and comfort. As the
lens materials have improved, the popularity of CL wear has
increased; currently, a large number of people, from children
to the elderly, wear CL. With an increased population of CL
wearers, complications related to inappropriate CL use and
care  are  of  serious  concern.  Among  these  complications,
corneal neovascularization (corneal NV) has frequently been
reported [1].
In general, the normal cornea is a nonvascular tissue
whose metabolism for maintaining transparency is dependent
on oxygen and nutrients. When a CL is worn, there are two
major oxygen delivery systems regulating the oxygen tension
at the tear-lens interface: the diffusion of oxygen from the air
through the lens material and the pumping of oxygenated tears
beneath  the  lens  during  lens  movement  by  blinking  [2].
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Prolonged hydrophilic CL wear induces a state of hypoxia to
the corneal surface frequently associated with inflammation
and neovascularization of the corneal surface. Hypoxia is
believed to be the principle contributor to adverse effects of
CL wear [3,4].
A  master  regulator  of  the  hypoxic  response  is  the
transcription factor hypoxia-inducible factor 1 (HIF-1), which
consists of an α-subunit whose proteasomal degradation and
thus relative abundance are regulated by oxygen tension, and
a constitutively expressed β-subunit [5]. HIF-1 transactivates
the expression of proangiogenic genes in response to hypoxic
conditions and plays important roles in vasculogenesis and
angiogenesis [6,7]. Binding of HIF-1 to the hypoxia response
element of the vascular endothelial growth factor (VEGF)
promoter results in transcriptional activity [8]. VEGF, a potent
and specific mitogen for vascular endothelial cells, is a critical
mediator of corneal NV. Animal studies have shown that
VEGF overexpression is sufficient to induce corneal NV in
the eye [9,10], whereas inhibition reduces this effect [11].
VEGF is also expressed in laser-induced corneal NV [12] and
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864surgically excised corneal NV membranes [13], and multiple
preclinical and clinical trials have proved that anti-VEGF
strategies were effective as potential therapeutic agents for the
treatment of corneal NV [14].
Because  HIF-1α  activates  the  transcription  of  VEGF,
which is required for corneal NV, it is possible that hypoxia
may mediate corneal NV through the induction of HIF-1α and
VEGF. However, little is known about this; even less is known
about  the  upstream  signaling  events  that  are  activated  by
hypoxia and that mediate its effects in corneal NV. The similar
and overlapping activities of VEGF and HIF-1α calls for a
study of the temporal relationship in the expression of these
two autocoids. The current study was undertaken to further
substantiate  the  cause  and  effect  relationship  between
HIF-1α, VEGF expression, and neovascularization in a mouse
model of closed eye with CL wear. We determined the time
dependent expression of HIF-1α and correlated it to that of
VEGF expression in the model. Herein, we demonstrated that
shRNA targeting corneal HIF-1α inhibited corneal NV further
supporting the role of HIF-1α as an angiogenic pathway in the
cornea.
METHODS
Design of gene targets and shRNA: ShRNA sequences were
derived from the coding sequence of mouse HIF-1α. The
RNAi-Ready pSIREN-RetroQ vector (Clontech, Palo Alto,
CA)  was  used.  Double  stranded  (ds)  oligonucleotides
encoding HIF-1α shRNA were chemically synthesized and
contained 5′-BamHI and 3′-EcoRI sites for insertion. The
HIF-1α shRNA sequences were as follows: RNAi-A, 5′-gat
ccG ATG CTT ACA CAC AGA AAT GTA GTG CTC CTG
GTT GCA TTT CTG TGT GTA AGC ATC ttt ttt g-3′; RNAi-
B, 5′-gat ccG GTC ACC ACA GGA CAG TAC ATA GTG
CTC CTG GTT GTG TAC TGT CCT GTG GTG ACC ttt ttt
g-3′. The sequence used as control did not encode for any
meaningful fragment 5′-gat ccG CAA AGG TCG ACT ACC
ACG ATA GTG CTC CTG GTT GTC GTG GTA GTC GAC
CTT TGC ttt ttt g-3′). Oligonucleotides were inserted into the
vector  using  the  BamHI  and  EcoRI  sites  immediately
downstream of the U6 promoter. The recombinant vectors
were  named  as  HIF-1α  RNAi-A,  HIF-1α  RNAi-B,  and
Vehicle-RNAi.
shRNA transfection and hypoxia induction in vitro: Simian
virus  40-immortalized  human  corneal  epithelial  cells
(HCECs)  were  provided  by  Choun-Ki  Joo  (The  Catholic
University of Korea, School of Medicine, Seoul, Korea). The
cells were cultured in DMEM/F-12 (1:1) media, 5% fetal
bovine serum (FBS; Gibco-BRL, Grand Island, NY), 5 μg/ml
insulin (Sigma, St. Louis, MO), 0.1 ng/ml cholera toxin (EMD
Biosciences, San Diego, CA), 10 ng/ml human epidermal
growth factor (hEGF; R&D Systems, Minneapolis, MN), and
0.5% dimethyl sulfoxide (DMSO; Sigma) in a humidified 5%
CO2 incubator at 37 °C [15]. HCECs were grown to 80%
confluence. The recombinant vectors were transfected into
HCECs  using  Effectence  Transfection  Reagent  (Qiagen
GmbH, Hilden, Germany) according to the manufacturer's
protocol.  Thirty-six  hours  after  transfection,  hypoxia  was
induced  in  the  cells  by  the  addition  of  CoCl2  to  a  final
concentration of 1 mM in each well. Five hours after CoCl2-
induction the supernatant was removed from all wells and
adherent cells were collected. For detecting expression of
HIF-1α, western blotting was performed on the collected cells.
Experiments were repeated three times.
Animals  and  samples:  All  animal  experiments  were
performed  in  accordance  with  the  guidelines  of  the
Association  for  Research  in  Vision  and  Ophthalmology
Statement for the Use of Animals in Ophthalmic and Vision
Research. BALB/C mice of both sexes (male:female=1:1), 8–
10-weeks  old,  were  purchased  from  the  Institution  of
Laboratory Animal Sciences (Chinese Academy of Medical
Sciences, Beijing, China) and were housed at the Shandong
Eye  Institute  Animal  Facility.  Briefly,  the  mice  were
anesthetized  intraperitoneally  with  ketamine  (37.5  mg/ml)
and xylazine (1.9 mg/ml). Proparacaine hydrochloride (0.5%)
was used for topical anesthesia. Only the right eye (OD) of
each mouse was used for CL wear; the left eye (OS) was
undisturbed.
The Etafilcon A lens (Acuvue, Jacksonville, FL) were
prepared  with  a  microkeratome  and  punched  with  a
3.5 mm trephine. Following the creation of some standard
3.5 mm lenses, the small hydrophilic CL was placed onto the
proptosed OD in a stacked fashion (2 lenses, one on top of the
other) and the eye was gently reposited. To keep the lenses in
place, 5–7 interrupted 10–0 silk sutures were placed through
the superficial tarsus of both eyelids with care taken not to
penetrate the conjunctival tissues. Immediately after surgery,
0.3% ofloxacin eye ointment (Tarivid; Santen, Osaka, Japan)
was administered to the palpebral margin.
For gene therapy, preparations were injected into the
subconjunctival  site  1  h  before  surgery  of  the  CL  wear.
Briefly,  a  needle  pierced  into  the  conjunctiva  from  the
corneoscleral limbus, and 5 μl of shRNA (1 μg/μl) or saline
was  injected.  Control  animals  were  only  treated  with  the
surgery of the CL wear. Each group contained ten BALB/C
mice. At 4, 7 and 10 days after surgery mice were anesthetized
and  the  eyelid  sutures  and  lenses  were  removed.  Cornea
photographs were taken with a camera mounted on the slit-
lamp  microscope  (Zeiss,  Jena,  Germany)  under  the  same
magnification.  Neovascularization  of  each  cornea,  as
described  by  others  [16,17],  was  determined  by  a  blind
examiner  to  minimize  the  observer’s  bias.  Briefly,  the
neovascularization score=(distance from the limbus to the end
point  of  the  cornea  neovascularization/distance  from  the
limbus to the center)/0.17. Each cornea received an exact
score. Scores were concluded representatively as follows: 0
(no visible vessels in the cornea), +1.5 (1/4 distance to center),
+2 (1/3 distance to center), +3 (1/2 distance to center), +4 (2/3
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865distance  to  center),  +4.5  (3/4  distance  to  center),  and  +6
(vessels reach center).
Reverse-transcription PCR: Total RNA was prepared from
each cornea, using the NucleospinRNA kits (BD Biosciences,
Palo  Alto,  CA),  and  reverse  transcribed  into  first-strand
cDNA, using Primescript™ First-Strand cDNA Synthesis kit
(TaKaRa, Dalian, China). Each group contained three corneal
tissues. Gene-specific cDNA fragments were amplified with
DNA polymerase (Tiangen, Beijing, China). The expression
of  genes  was  normalized  to  glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). The primer sequences for these
reactions were shown in Table 1. PCR amplification products
were analyzed by agarose gel electrophoresis.
Antibodies and western blotting: Total protein was prepared
from  each  cornea,  using  radio  immunoprecipitation  assay
(RIPA) buffer (50 mmol/l Tris pH 7.4, 150 mmol/l NaCl, 1%
Triton  X-100,  1%  sodium  deoxycholate,  0.1%  sodium
dodecyl sulfate [SDS], sodium orthovanadate, and sodium
fluoride;  Galen,  Beijing,  China),  and  quantified.  Protein
(50 μg in 15 μl loading buffer) was resolved in 10% sodium
dodecyl sulfate PAGE (SDS–PAGE) gel and then transferred
to  a  polyvinylidene  difluoride  membrane  (Millipore,
Billerica, MA). The blots were blocked in 5% nonfat dry milk
dissolved in Tris-buffered saline Tween-20 (TBST; 20 mmol/
l Tris, pH 7.5, 0.5 mmol/l NaCl, 0.05% Tween-20) for 1 h and
then incubated with the primary antibody in TBST for 1 h,
followed  by  incubation  with  horseradish  peroxidase-
conjugated  secondary  antibody  (Amersham  Biosciences,
Uppsala, Sweden) for 1 h. All incubations were done at 25 °C,
and three washes with 10 ml TBST were applied between each
step. The membranes were then developed with SuperSignal
West  Femto  Maximum  Sensitivity  substrate  (Pierce
Biotechnology,  Rockford,  IL)  and  exposed  to  X-ray  film
(Kodak, Rochester, NY). The immunoreactive bands were
quantified using National Institutes of Health (NIH) Image
1.62 software (NIH, Bethesda, MD).
Primary  antibodies  included  anti-VEGF  antibody
(Abcam,  Cambridge,  MA),  anti-HIF-1α  antibody  (abcam,
Cambridge,  MA),  anti-GAPDH  antibody  (Kangchen,
Shanghai, China), anti-phosphorylated nuclear factor-kappa
B  (P-NF-κB)  antibody,  and  anti-NF-κB  antibody  (Cell
Signaling Technology, Danvers, MA). All the experiments
reported in this study were performed three times, and the
results  were  reproducible.  For  each  sample,  the  levels  of
proteins of interest were normalized to that of GAPDH.
Immunofluorescence  and  immunohistochemistry:  Eyeballs
were  snap-frozen  in  optimal  cutting  temperature  (OCT)
compound  (Sakura  Finetechnical,  Tokyo,  Japan).
Cryosections  (6  μm)  were  prepared  from  OCT-embedded
eyeballs and were fixed in ice-cold acetone for 10 min. The
sections were blocked with 10% normal goat serum for 15 min
and  stained  with  anti-VEGF  antibody  and  anti-HIF-1α
antibody (abcam, Cambridge, MA) overnight at 4 °C. Sections
were washed and stained for 30 min at 37 °C with rhodamine-
conjugated  goat  anti-mouse  immunoglobulin  G  (IgG)
secondary  antibody  (Santa  Cruz,  Inc.,  CA).  After
counterstaining with 4,6-diamidino-2-phenylindole (DAPI),
the stained sections were viewed under an Eclipse TE2000-U
microscope (Nikon, Tokyo, Japan). Negative controls were
performed by omitting primary antibodies.
Eyeballs  were  fixed  in  10%  buffered  formalin,  and
embedded in paraffin. Paraffin sections of 4 μm in thickness
were deparaffinized, rehydrated, and stained with anti-P-NF-
κB antibody using routine protocols.
Statistical  analysis:  Data  are  presented  as  mean±standard
deviation  (SD).  The  differences  between  control  and
experimental conditions were analyzed using the one-way
ANOVA (ANOVA) and Student-Newman-Keul's (SNK) test.
The  statistical  differences  were  evaluated  by  SPSS  11.5
software  (SPSS  Inc.,  Chicago,  IL),  and  a  p<0.05  was
considered significant.
RESULTS
CL wear induced corneal NV: Corneal NV was apparent in
eyes with CL wear as early as 4 days after its placement
(Figure 1B). The neovascular response increased with time
encompassing larger area of the cornea by day 7–10 after CL
wear (Figure 1C, D). Quantitative analysis showed that the
neovascular response to CL wear in eyes receiving the CL
wear was upregulated by 1.56 and 2.36 fold on day 7 and 10
over the neovascular response respectively by day 4 of CL
wear (Table 2).
The  changes  of  HIF-1α  and  VEGF  abundance  were
confirmed by RT–PCR at mRNA level (Figure 2A,B) and by
western  blotting  (Figure  2C,D)  or  immunofluorescence
TABLE 1. THE SEQUENCES AND SIZE PRODUCT FOR RT–PCR PRIMERS.
Gene name Primer sequences (F) Primer sequences (R) Product
length
GAPDH GGTGAAGGTCGGTGTGAACGGA TGTTAATGGGGTCTCGCTCCTG 246 bp
HIF-1α GGTATTATTCAGCACGACTT GGAGACATTGCCAGGTTTAT 323 bp
VEGF GAGCAGAAGTCCCATGAAGTG CATGGTGATGTTGCTCTCTGA 213 bp
IL-1β GCCCATCCTCTGTGACTCAT AGGCCACAGGTATTTTGTCG 230 bp
MMP-2 CCCGATCTACACCTACACCAA AAACCGGTCCTTGAAGAAGAAC 217 bp
MMP-9 CGTCGTGATCCCCACTTACTA AAGATGAACGGGAACACACAG 237 bp
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866(Figure  3)  at  the  protein  level.  Collectively,  these  results
implied  that  HIF-1α  and  VEGF  were  involved  in  the
pathogenesis of CL-induced corneal NV.
In vitro efficacy of HIF-1α shRNA: HCECs exhibited very low
levels of HIF-1α expression. HIF-1α was upregulated by 5.5
and 21.6 fold after 3 h or 5 h induction of CoCl2 over normal
cornea  (Figure  4A,B).  Therefore,  HCECs  overexpressing
HIF-1α induced by CoCl2 for 5 h were used to evaluate the
efficacy  of  shRNA  targeting  HIF-1α.  Western  blotting
analysis  revealed  that  both  HIF-1α  RNAi-A  and  HIF-1α
Figure 1. Representative pictures depicting corneal NV in eyes at days 4, 7, and 10 after CL wear.
TABLE 2. QUANTITATIVE ANALYSIS OF CORNEAL NV 4, 7 AND 10 DAYS AFTER CL WEAR (MEAN±SD).
    Neovascularization score*  
Groups Number of eyes Maximum Minimum Mean p (versus normal)
Normal 10 0 0 0 ʵ
4d 10 2.14 0.98 1.53±0.35 0.000
7d 10 3.24 1.67 2.39±0.48 0.000
10d 10 5.49 1.81 3.59±1.10 0.000
Neovascularization was scored according to the distance from the limbus to the farthest end of the new vesicles: 0 (no visible
vessels  in cornea), +1.5 (1/4 distance to center), +2 (1/3 distance to center), +3 (1/2 distance to center), +4 (2/3 distance to
center), +4.5 (3/4 distance to center) and +6 (vessels reach center).
Figure  2.  Relationship  between  the
duration of closed eye CL wear, corneal
HIF-1α and VEGF levels. A: Corneal
RNA was extracted and RT–PCR was
performed  with  HIF-1α,  VEGF,  and
GAPDH  specific  primers.  C:  western
blotting  analysis  was  performed  as
described in Methods. Corneal HIF-1α
and VEGF levels were normalized to
that  of  GAPDH.  B,  D:  Densitometry
analysis expressed in arbitrary units as
the  mean±SD,  n=3,  **p<0.01,  as
compared  with  HIF-1α  of  normal
cornea.  ∆ p<0.01,  as  compared  with
VEGF of normal cornea.
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867RNAi-B  substantially  attenuated  protein  levels  of  HIF-1α
induced by CoCl2 (Figure 4C). HIF-1α RNAi-A attenuated
endogenous HIF-1α protein levels with a maximum blockage
of 60% compared with the Vehicle-RNAi (Figure 4C,D).
HIF-1α  shRNA  inhibited  corneal  NV:  Corneal  NV  was
apparent in eyes with CL wear on day 10 after its placement.
In eyes treated with saline, the neovascular response increased
with larger area of the cornea by day 10 after CL wear (Figure
5C).  Similar  neovascular  response  was  observed  in  eyes
treated with Vehicle-RNAi (Figure 5D). In contrast, corneal
NV was markedly reduced in eyes receiving subconjunctival
injections of HIF-1α specific shRNA (RNAi-A) (Figure 5E)
as compared to eyes treated with the vehicle-RNAi or saline.
Quantitative analysis showed that the neovascular response to
CL wear in eyes receiving the HIF-1α RNAi-A injection was
inhibited by about 69% and 72% at day 10, respectively, when
compared with Vehicle-RNAi or saline group (Table 3).
HIF-1α  shRNA  decreased  the  corneal  expression  of
angiogenic factors and nuclear factor-κB pathway activity in
CL  wear  corneas:  The  effect  of  shRNA  treatment  on
HIF-1α expression was assessed by RT–PCR and western
blotting analysis. As seen in Figure 6A,C, HIF-1α RNAi-A
indicated  a  significant  inhibition  of  HIF-1α  mRNA  and
protein  expression  in  HIF-1α  RNAi-A  treated  eyes.
Expression of VEGF, MMP-2/9, and IL-1β in corneas was
measured by using western blotting or RT–PCR. We found
Figure 3. Immunofluorescence staining of HIF-1α and VEGF in cornea at day 4 and 7 after CL wear. The arrows indicated the positive staining
of HIF-1α and VEGF in the corneal epithelium of each group. A: HIF-1α expression in normal cornea. B: HIF-1α expression in cornea at day
4. C: HIF-1α expression in cornea at day 7. D, H: Control cornea at day 7. E: VEGF expression in normal cornea. F: VEGF expression in
cornea at day 4. G: VEGF expression in cornea at day 7. Magnification: 400×.
Figure 4. Inhibition of HIF-1α induced
by CoCl2 by HIF-1α specific shRNA in
HCECs.  A:  HIF-1α  was  upregulated
after 3 h and 5 h induction of CoCl2 over
normal  corneas.  B:  Quantitative
analysis of HIF-1α protein expression in
HCECs. Results were mean±SD, n=3,
**p<0.01 as compared with 0 h group.
C: western blotting analysis of HIF-1α
expression  in  HCECs  treated  with
shRNA  targeting  HIF-1α  (RNAi-A,
RNAi-B)  and  nonspecific  shRNA
(Vehicle-  RNAi)  and  incubated  with
CoCl2.  D:  Quantitative  analysis  of
HIF-1α  expression  from  panel  C.
Results  are  mean±SD,  n=3,  *p<0.05,
**p<0.01  as  compared  with  CoCl2
group.
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868that HIF-1α RNAi-A effectively inhibited VEGF, MMP-2/9,
and IL-1β expression in the CL wear model (Figure 6). Lastly
we examined the activity of NF-κB pathway and found that
HIF-1α  RNAi-A  significantly  reduced  NF-κB
phosphorylation without changing the total amount of NF-κB
(Figure 7).
DISCUSSION
Contact  lenses  interact  mechanically  with  the  cornea  and
modify the physiologic processes of corneal tissue. These
changes  may  lead  to  reduced  corneal  function  [18].  It  is
necessary  to  differentiate  corneal  changes  that  are
physiologically acceptable from those that are pathologic.
Clinicians, biochemists, engineers, and vision scientists have
performed  countless  research  studies  to  understand  the
etiology of these changes to enhance the safety of CL wear.
The major consequence of CL wear is chronic hypoxia, with
corresponding hypercapnia [19].
Fitting a CL on the eye leads to a significant reduction in
the oxygen supply to the cornea, in the range of 8% to 15%,
depending on the gas permeability of the lens material used.
After prolonged corneal hypoxia, there is depletion of the
glycogen reserves of the cornea, diminished ATP (ATP), and
ultimately a slowing of the water transport system in the
endothelium. The combined effects of the accumulation of
lactic acid in the stroma and a decrease in the pumping action
of the endothelium result in increased corneal edema.
Corneal NV is a normal (albeit undesirable) vascular
response to CL wear, and some vascular response occurs with
almost  all  CL.  There  are  several  steps  in  the
neovascularization process: (1) limbal hyperemia, a dilatation
of existing limbal capillaries, is reversible and common; (2)
superficial neovascularization (pannus) is the progression of
limbal  hyperemia  and  the  penetration  of  vessels  into  the
superficial cornea; (3) deep stromal neovascularization results
from  chronic  hypoxia  that  may  progress  to  an  active
Figure 5. Effect of shRNA treatment on
corneal  NV.  Representative  pictures
depicting  corneal  NV  in  normal  and
control eyes (A, B) and in eyes receiving
subconjunctival injections of saline (C),
nonspecific  shRNA  (Vehicle-  RNAi;
D) or HIF-1α specific (RNAi-A; E) at
day 10 after CL wear.
TABLE 3. HIF-1Α SHRNA ON CORNEAL NV AFTER 10 DAYS OF CL WEAR (MEAN±SD).
    Neovascularization score*  
Groups Number of eyes Maximum Minimum Mean p (versus control)
Normal 10 0 0 0 ʵ
Control 10 5.49 1.81 3.59±1.1 ʵ
Saline 10 5.20 2.61 4.05±0.75 0.141
Vehicle-RNAi 10 5.11 2.01 3.64±1.02 0.867
HIF-1αRNAi-A 10 2.83 0 1.13±0.96 0.000
Neovascularization was scored according to the distance from the limbus to the farthest end of the new vesicles: 0 (no visible
vessels  in cornea), +1.5 (1/4 distance to center), +2 (1/3 distance to center), +3 (1/2 distance to center), +4 (2/3 distance to
center), +4.5 (3/4 distance to center) and +6 (vessels reach center).
Molecular Vision 2012; 18:864-873 <http://www.molvis.org/molvis/v18/a91> © 2012 Molecular Vision
869inflammatory or fibrovascular deep pannus; and (4) there may
be an intracorneal hemorrhage [19].
Although corneal NV has been reported during extended
wear of disposable and conventional lenses, quantitative and
comparative data are lacking. It is especially common with
large and thick CL and results in development of new corneal
vessels in up to 20% of wearers [19]. No single theory can
account for corneal NV; rather, several factors may contribute
[20].  Proposed  theories  take  the  following  aspects  into
account:  metabolic  factors  (hypoxia,  lactic  acid,  edema);
angiogenic suppression; vasostimulation; and neural control.
One  or  all  of  these  stimuli  are  present  during  CL  wear,
particularly overnight wear. Whatever classification system is
used, the most important factor is CL-induced tissue hypoxia.
HIF-1α  is  regulated  through  ubiquitin-mediated
degradation under normoxic conditions and stabilization and
activation under conditions of hypoxia. It is well known that
under hypoxic condition, binding of HIF-1α to the hypoxia
response  element  (HRE)  of  VEGF  promoter  results  in
transcription activity [21-23]. Therefore, we determined the
time dependent expression of HIF-1α and correlated it to that
of VEGF expression in the mouse model of closed eye CL-
induced injury. In this model, hypoxia is believed to be the
principle contributor to adverse effects of CL wear [4,24]. Our
results showed that mRNA and protein levels of HIF-1α in the
cornea  epithelium  of  CL  wear  in  response  to  hypoxia,
followed  by  increasing  expression  of  VEGF.  mRNA  and
protein levels of HIF-1α and VEGF decreased dramatically
after transfection with an HIF-1α specific shRNA vector.
Based on these results, we presumed that hypoxia may
mediate corneal NV through HIF-1α-regulated VEGF in this
model.  To  further  elucidate  the  mechanism  for  this,  we
investigated which related factors were involved in regulating
corneal NV. Western blotting and RT–PCR assay showed that
such  antiangiogenic  activity  might  involve  a  decrease  of
IL-1β and MMP-2/9 expression. As a principal degrader of
extracellular  matrix  (ECM),  MMP-2/9  were  proposed  to
facilitate the growth of new blood vessels by breaking down
the ECM and amplifying effect of other angiogenic factors
[25], thus representing a logical target for anti-angiogenic
therapy. IL-1β is one of the key mediators involved in many
inflammatory responses [26-28].
On the other hand, NF-κB plays an important role in
IL-1β  related  inflammatory  diseases,  including  various
corneal diseases [29,30]. NF-κB is an important therapeutic
target in chronic inflammatory diseases, enabling significant
downregulation  of  macrophage-produced  proinflammatory
cytokines [31-33]. There are conflicting data in the literature
regarding the role of NF-κB in VEGF signaling. One group
has  been  unable  to  demonstrate  an  effect  of  the  NF-κB
pathway on the expression of VEGF. Others have shown that
the  upregulation  expression  of  VEGF  is  regulated  by
increased NF-κB activity [34,35]. Signaling via the NF-κB
pathway has recently been suggested to play a role in the
Figure 6. Effects of HIF-1α shRNA on
HIF-1α,  VEGF,  MMP-2/9,  and  IL-1β
expression in corneas with CL. HIF-1α
and VEGF were detected by RT–PCR
(A)  and  western  blotting  (C)  while
MMP-2/9 and IL-1β were detected by
RT–PCR (A). GAPDH was used as the
internal control in all cases. As shown
by the analysis results (B, D) compared
with the control group, HIF-1α RNAi-A
significantly  down-regulated  the
expression levels of VEGF, MMP-2/9,
and  IL-1β.  Three  independent
experiments were conducted, and data
were  shown  as  mean±SD  *p<0.05,
**p<0.01  as  compared  with  control
group.
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870transcriptional regulation of the VEGF gene in various cancer
cells [36,37]. In addition, administration of NF-κB antisense
oligonucleotides partially inhibited the TNFα and platelet-
activating-factor-dependent production of VEGF in human
vascular endothelial cells [38].
In summary, our study directly confirmed that inhibition
of  HIF-1α  expression  attenuated  corneal  NV  induced  by
prolonged CL wear. The results strongly implicated corneal
HIF-1α as a component of the inflammatory and neovascular
cascade initiated by CL wear. Recent interest in inhibiting
neovascularization has focused on VEGF [39]. Together with
the results presented here, raised the possibility of a new
approach to the problem of preventing corneal NV that targets
the HIF-1α system. Preliminary findings also supported a
functional role for NF-κB in the VEGF signaling pathway, but
more studies in depth should be done to expound the exact
mechanisms for such gene therapy.
Figure  7.  Measurement  of  nuclear
factor-kappa  B  (NF-κB)  pathway
proteins by western blotting in corneas.
A: Total lysates from murine corneal
tissue lysates were analyzed by western
blotting  for  their  level  of  NF-κB
activation by detecting phosphorylated
NF-κB  (P-NF-κB),  and  total  NF-κB
protein. As shown by the analysis results
(B),  HIF-1α  RNAi-A  significantly
down-regulated  NF-κB
phosphorylation  expression.  Three
independent  experiments  were
conducted,  and  data  were  shown  as
mean±SD **p<0.01 as compared with
the  Vehicle-RNAi  group.  C:
Immunohistochemistry  staining  of  P-
NF-κB in corneas with CL. The arrows
indicated the positive staining of P-NF-
κB  in  the  corneal  epithelium  of  each
group.  P-NF-κB  was  located  to  the
nucleus. Magnification: 400×.
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